Author Archives: S Anne Montgomery

From the Editor: November-December 2023

As I look forward to retirement and revisit 35 years in publishing, I marvel at all the adventures that a graduate degree in comparative literature can lead to. I’d always dabbled in biology, but for some years, literature, languages, and teaching won out. By the late 1980s, leaving a dissertation unfinished didn’t help me compete for full-time community college teaching gigs. Carpentry and school-bus driving were okay for a while, and playing baroque recorder music garnered extra grocery money, but…

September 2023: From the Editor

With another September comes another collective sprint to the end of the year. Because of our three-month minimum span from receipt of a manuscript to its publication, we already are planning our January–February issue. But between now and then, we have plenty to do. The publication’s editors, Dan Stanton’s BioProcess Insider team, and our conference colleagues are gathering up ideas, comparing notes, evaluating trends, and creating editorial and conference calendars for 2024. The BPI conference and colocated meetings are coming…

How Did the Pandemic Adjust the CDMO Landscape, and How Will This Sector Change Moving Forward?

The BPI Theater at BIO began its program on Monday afternoon, 5 June 2023, with a panel titled “How Did the Pandemic Adjust the CDMO Landscape, and How Will This Sector Change Moving Forward?” Moderator S. Anne Montgomery introduced the panelists. Richard Richieri is the chief operations officer at Avid Bioservices, where he is responsible for current good manufacturing practice (CGMP) operations that include process development, technical operations, facilities, supply-chain management, and manufacturing. He’s been with Avid for more than 18…

May 2023: From the Editor

While editing and proofreading an issue, we often see statements that suggest other intriguing angles to explore. But deadlines loom, and our notes to follow up on those ideas can get lost in the shuffle. And because we pursue a good portion of our manuscripts (cue image of editor chasing after conference speakers in crowded hallways), those notes have value. Seemingly casual statements in talks and manuscripts can help us focus our acquisition efforts. Working through those mental “loops,” adding…

April 2023: From the Editor

The biopharmaceutical industry is continually reinventing itself. It evolved from a science-driven entrepreneurial approach and has worked over five decades to weave its network of business, regulatory, and process-development modes somewhat after the fact. The origin of so many bioprocesses in academic research laboratories prompted some of us in the editorial world to propose article series on “biobusiness 101 for scientists” back even in the early 1990s. Much of the industry’s progress toward its current form depended on adapting processes…

March 2023: From the Editor

The first event that we editors attend each year usually is the annual WCBP (Well-Characterized Biopharmaceutical Products) conference hosted by CASSS, formerly the California Separations Science Society. Held in Washington, DC, each January, the meeting is prefaced by a day-long offering of two CMC Strategy Forums. The combined event brings together scientists and regulators from around the world to explore current issues in biopharmaceutical development from a chemistry, manufacturing, and controls (CMC) perspective. Presentations often include updates and progress reports…

January-February 2023: From the Editor

The “happy new year” routines are pretty much over with by now, with their many variations on “shhh, don’t scare the new year away” and “2023 has got to be an improvement” among other expressions of “good riddance to 2022” and our collective anxiety over ongoing global crises. Meanwhile, as it has done since its inception, the biopharmaceutical industry continues adapting to survive and thrive as it celebrates considerable milestones. BPI devoted much of 2022 to retrospective analyses of progress…

November-December 2022: From the Editors

With this issue, we bid a reluctant farewell to our managing editor as she retires. Cheryl and I have known her and appreciated her friendship for 26 years. Her accumulated knowledge of cell and gene therapy development and the ease with which she can interpret the nuances of automation, digitalization, and equations will be sorely missed. To honor her time with us, I asked her to share her perspectives below. Maribel — it has been a thorough joy to work…

October 2022: From the Editor

Happy autumn! I am writing this a few days before the editors head to Biotech Week Boston and the BPI conference. This is my first travel since January of 2020, and I am eager to see everyone again. As usual, the fall months coincide with our finalizing next year’s editorial calendar. I will be able to share those details (and other BPI news) with you in our next issue. One major project that came our way a few months ago…

20th Anniversary Issue: From the Editors

Founded in the middle of 2002, BPI published its first issue in January of 2003. Our 20th-anniversary issue thus takes the form of a state-of-the-early-21st-century industry report. Assembling this content has reinforced our appreciation of the remarkable paths that this industry has taken and continues to take — and our journey alongside it. Having worked as editors in this industry since August 1988 (Montgomery) and September 1996 (Scott), we’ve found it difficult to maintain a chronological grasp of developments —…